en.Wedoany.com Reported - Colombia's Congress has passed a new bill authorizing the domestic production of radiopharmaceuticals and key nuclear medicine consumables for cancer diagnosis and treatment, aiming to end the current reliance on imports, reduce external dependency, and ensure timely patient access to treatment. Under the new law, related production activities must be carried out in facilities that meet national nuclear safety and radiation protection standards and are subject to oversight by the Colombian Nuclear Regulatory Authority.

The products covered by the bill primarily include Iodine-131 for thyroid cancer treatment, Lutetium-177 for targeted therapy of neuroendocrine tumors, and radioactive tracers for positron emission tomography, all of which represent peaceful applications of nuclear technology in medicine. Local production will rely on research reactors or cyclotrons, equipped with corresponding radiochemical hot cell production lines, and operated by personnel with nuclear technology training qualifications.

The Colombian Nuclear Regulatory Authority will oversee the entire chain of production licensing, possession of radioactive materials, transportation, and waste management. Authorities stated that the implementation of this bill is expected to significantly reduce the costs of radiotherapy and nuclear medicine diagnostics, shorten the risk of supply chain disruptions, save thousands of cancer patients' lives, and simultaneously advance the country's nuclear science and technology capacity building.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com